Daily Cosmetic Research Analysis
Three impactful studies in cosmetic and aesthetic medicine stand out today: a randomized controlled trial shows a micro‑anchor skin closure device accelerates early scar cosmesis versus sutures; an updated EYE-CODE protocol offers a pragmatic, time-critical algorithm for retinal artery occlusion after filler injections; and a preclinical sericin/nano‑hydroxyapatite hydrogel demonstrates promise as a biocompatible dermal filler with collagen-regenerative potential.
Summary
Three impactful studies in cosmetic and aesthetic medicine stand out today: a randomized controlled trial shows a micro‑anchor skin closure device accelerates early scar cosmesis versus sutures; an updated EYE-CODE protocol offers a pragmatic, time-critical algorithm for retinal artery occlusion after filler injections; and a preclinical sericin/nano‑hydroxyapatite hydrogel demonstrates promise as a biocompatible dermal filler with collagen-regenerative potential.
Research Themes
- Early cosmetic outcomes and wound closure innovation
- Emergency management of filler-associated retinal artery occlusion
- Biomaterials for dermal filling and collagen regeneration
Selected Articles
1. A novel skin closure device accelerates early cosmesis in orthopaedic surgical incisions: a randomised controlled trial.
In a single-blind RCT of 83 patients (149 incisions), a micro‑anchor adhesive closure device improved early cosmetic scores (HWES) at 2 weeks and 2 months versus sutures for ≤2 cm incisions and improved 2‑month scores for >2 cm incisions; groups were comparable at 1 year. The device may expedite attainment of satisfactory cosmesis after orthopaedic sports procedures.
Impact: Provides randomized evidence that an adhesive micro‑anchor device accelerates early cosmesis without compromising long-term scar appearance, informing closure choice where early appearance matters.
Clinical Implications: For small to moderate orthopaedic incisions, micro‑anchor adhesive closure may be preferred when early cosmetic appearance and patient satisfaction are prioritized, with expectation of similar 1‑year scar quality.
Key Findings
- Among ≤2 cm incisions (n=111), micro‑anchor closure significantly improved HWES at 2 weeks and 2 months versus sutures.
- Among >2 cm incisions (mean 7.74 cm; n=38), micro‑anchor closure improved HWES at 2 months.
- No significant cosmetic differences between groups at 1 year across incision sizes.
Methodological Strengths
- Randomized, prospective, single-blind design with blinded outcome assessment
- Stratification by incision length and use of a validated cosmetic scale (HWES)
Limitations
- Single-center study with modest sample size
- No significant differences at 1 year; study not powered for complications or cost-effectiveness
Future Directions: Multi-center RCTs powered for patient-reported outcomes, complications, cost, and different anatomical sites; head‑to‑head comparisons with other adhesive or staple devices.
OBJECTIVE: Cosmesis of surgical incisions can greatly impact postoperative patient satisfaction. This study aimed to compare the rate and overall cosmetic improvement of orthopaedic surgical incisions between conventional suture closure and a novel skin closure device. METHOD: In this single-blind, randomised, prospective controlled trial, a consecutive series of patients undergoing orthopaedic sports medicine procedures of the knee, shoulder and elbow were randomised to undergo wound closure via either conventional suture or a micro-anchor skin closure device (BandGrip; BandGrip, US). Wounds were stratified by incision length (small ≤2cm and large >2cm). Wound cosmesis was evaluated by two blinded observers' ratings according to the Hollander Wound Evaluation Scale (HWES) at two weeks, two months and one year postoperatively. For both small and large incisions, mean HWES was compared between groups at each timepoint. RESULTS: A total of 149 incisions were evaluated from 83 patients, including 111 incisions ≤2cm and 38 incisions >2cm. Among incisions ≤2cm, HWES ratings were significantly improved at two weeks and two months postoperatively for incisions closed with a micro-anchor skin closure device, whereas no significant differences between treatment groups were detected at one year postoperatively. Among incisions measuring >2cm (mean incision length = 7.74cm), mean HWES ratings were improved using the micro-anchor adhesive device at two months postoperatively, while HWES ratings were comparable at one year postoperatively. CONCLUSION: A novel micro-anchor skin closure device achieves comparable cosmetic outcomes to conventional suture and may reach satisfactory cosmesis more rapidly following orthopaedic sports medicine surgery.
2. EYE-CODE Protocol for the Nonophthalmologist for Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Soft-Tissue Fillers: 2025 Update.
This updated, evidence-informed EYE-CODE protocol provides a clear, in-office algorithm for aesthetic physicians to rapidly assess and treat retinal artery occlusion after soft-tissue filler injections, emphasizing immediate referral, ocular massage, intraocular pressure reduction, and attempts to dissolve the embolus. It standardizes early steps within the narrow therapeutic window before irreversible ischemia.
Impact: Addresses a rare but catastrophic aesthetic procedure complication with actionable steps likely to improve time‑to‑treatment consistency across practices.
Clinical Implications: Provides non‑ophthalmologists with a structured, medication‑ready protocol to manage acute retinal ischemia immediately after filler injection, potentially preserving vision until ophthalmic care is established.
Key Findings
- Defines a stepwise EYE-CODE algorithm: call retinal referral, check vision/optic nerve, ocular massage, lower IOP, and attempt to dissolve filler embolus.
- Emphasizes use of medications commonly available in aesthetic practices to reduce IOP and improve perfusion during the critical window.
- Outlines treatments that emergency ophthalmologists can continue after initial office-based management.
Methodological Strengths
- Practical, standardized algorithm tailored to time-sensitive emergency in aesthetic practice
- Evidence-informed steps leveraging widely available medications and procedures
Limitations
- Consensus-based protocol without prospective clinical outcome validation
- Heterogeneity in embolus composition and treatment resources may affect generalizability
Future Directions: Prospective registries or pragmatic trials to evaluate visual outcomes with EYE-CODE, simulation-based training for rapid implementation, and filler-specific dissolution strategies.
BACKGROUND: Vision loss following a facial esthetic procedure with soft-tissue fillers is an event for which there is only a short treatment window to restore blood flow before irreversible ischemic damage occurs. OBJECTIVE: To provide a current standardized treatment approach for the management of retinal artery occlusion after intra-arterial injection of soft-tissue fillers. METHODS: This document provides an updated, simple, and evidence-based protocol for acute treatment in the office setting using the acronym EYE-CODE: EYE (I call retinal referral center), C (check vision and optic nerve function), O (ocular massage), D (decrease intraocular pressure), and E (erase filler). RESULTS: The EYE-CODE protocol assists esthetic physicians to determine the extent of vision loss and provides an initial treatment strategy using medications likely to be available in most practices. This includes agents that reduce intraocular pressure, improve retinal perfusion, and potentially dissolve the filler embolus and any associated blood clots. Suggestions are also made for treatments that can be continued by an emergency ophthalmologist. CONCLUSION: The EYE-CODE 2025 update provides physicians with a comprehensive reference for the management of retinal artery occlusion caused by soft-tissue filler injections.
3. A novel injectable Sericin/Nano-hydroxyapatite hydrogel as a dermal filler for soft tissue augmentation.
An ultrasonic, crosslinker‑free sericin/nano‑hydroxyapatite hydrogel forms within minutes, exhibits high swelling and injectability, and shows strong biocompatibility (hemolysis <2.5%). In a mouse wrinkle model it promoted collagen synthesis, elicited no inflammation, and demonstrated prolonged in vivo retention, supporting its promise as a dermal filler.
Impact: Introduces a natural, crosslinker‑free injectable biomaterial with antioxidant and collagen‑regenerative properties, addressing safety and durability needs in dermal fillers.
Clinical Implications: If validated in large‑animal and human studies, this hydrogel could provide a safer, longer‑lasting alternative or adjunct to current hyaluronic acid fillers for wrinkle reduction and soft‑tissue augmentation.
Key Findings
- Ultrasonication produced rapid gelation within minutes, yielding a uniform porous structure with >10-fold swelling and good injectability.
- Demonstrated strong antioxidant and anti-inflammatory properties with favorable biocompatibility: supported fibroblast proliferation and hemolysis rate <2.5%.
- In a mouse wrinkle model, the hydrogel promoted collagen synthesis, caused no inflammatory response, and showed prolonged in vivo retention.
Methodological Strengths
- Comprehensive physicochemical characterization coupled with in vitro cytocompatibility and in vivo efficacy testing
- Crosslinker-free ultrasonic fabrication reduces potential toxicity and simplifies manufacturing
Limitations
- Preclinical model only; no head-to-head comparison with standard hyaluronic acid fillers
- Long-term degradation, immunogenicity, and migration risk not evaluated in large animals
Future Directions: Benchmark against commercial fillers (rheology, lift capacity, longevity), conduct GLP toxicology and large-animal studies, and assess injection behavior and reversibility in clinically relevant tissues.
With the rapid advancement of medical aesthetics, particularly the expanding market for wrinkle reduction and facial rejuvenation, the demand for dermal fillers continues to rise. Injectable materials derived from natural sources offer significant potential in cosmetic applications due to their superior biocompatibility and bioactivity as soft tissue augmentation fillers. In this study, a novel Sericin/Nano-hydroxyapatite hydrogel was synthesized using ultrasonic technology, eliminating the need for cross-linking agents and simplifying the preparation process. The results showed that the hydrogel could form a gel in a few minutes under ultrasonication. Characterization analyses revealed a uniform porous structure. The hydrogel exhibited a swelling degree of over 10-fold and excellent mechanical properties, including injectability. Furthermore, the hydrogel demonstrated strong antioxidant properties, capable of mitigating inflammatory responses. Cytotoxicity and biocompatibility assessments in mouse fibroblasts demonstrated that the hydrogel supports cell proliferation without inducing toxicity, and exhibited good blood compatibility (hemolysis rate < 2.5 %). In a mouse wrinkle model, the hydrogel exhibited a favorable safety profile, elicited no inflammatory response, promoted collagen synthesis, and demonstrated prolonged in vivo retention. These findings highlight the Sericin/Nano-hydroxyapatite hydrogel as a promising dermal filler with superior mechanical properties and collagen-regenerating potential.